Overview

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Birdie Biopharmaceuticals HK Limited
Collaborator:
Seven and Eight Biopharmaceuticals Inc
Treatments:
Pembrolizumab